Jan 30 U.S. pharmaceutical wholesaler McKesson
Corp, which last week reached a deal to acquire
Germany's Celesio AG, reported on Thursday a 79
percent drop in quarterly net profit as one-time inventory and
other charges offset revenue gains.
For its full fiscal year ending March 31, McKesson said it
expects adjusted earnings per share from continuing operations
of $8.05 to $8.20 per share, down from a previous estimate of
$8.40 to $8.70 per share, due to higher acquisition and
For its fiscal third quarter ended Dec. 31, McKesson posted
a net profit of $64 million, or 28 cents per share, compared
with $298 million, or $1.24 per share, a year earlier.
Excluding one-time charges, the company earned $1.45 per
share, well short of the $1.84 per share forecast, on average,
by analysts, according to Thomson Reuters I/B/E/S.
Revenue rose 10 percent to $34.3 billion. Analysts had
expected $33.57 billion.
With the Celesio buyout, valued at about $8.5 billion
including debt, McKesson aims to further its push to become a
global leader in drugs distribution. The deal was secured after
the U.S. company reached agreements with two shareholders
controlling about 75 percent of Celesio shares.